Peptide Bioavailability: How Subcutaneous, Oral, and Nasal Delivery Routes Compare in Published Research

Bioavailability is the fraction of an administered compound that reaches systemic circulation in its active form. For peptides, this metric is shaped by molecular size, enzymatic degradation, membrane permeability, and the route of administration. Understanding how delivery method affects peptide bioavailability is central to interpreting study results, comparing formulations, and evaluating the translational potential of preclinical findings.

The Peptide Register catalogues bioavailability data across peptide profiles in its peptide database, providing researchers and clinicians with a structured reference for comparing delivery-related pharmacokinetic parameters.

Why Peptides Present Unique Bioavailability Challenges

Most peptides are between 2 and 50 amino acids in length, placing them in a molecular weight range (roughly 200 to 5,000 Da) that creates distinct pharmacokinetic challenges. Peptides in the 2 to 50 amino acid range face enzymatic degradation, poor membrane permeability, and rapid renal clearance, all of which limit bioavailability. Proteolytic enzymes in the gastrointestinal tract, blood plasma, and tissue compartments rapidly cleave peptide bonds. The hydrophilic character of most peptide sequences limits passive diffusion across epithelial membranes. Short circulating half-lives, often measured in minutes, further reduce the window of therapeutic exposure.

These factors explain why the same peptide can show dramatically different pharmacokinetic profiles depending on how it is delivered. For a foundational overview of peptide structure and how it differs from proteins and small molecules, see this explainer on peptide classification.

Subcutaneous Injection: The Reference Standard

Subcutaneous injection remains the most common delivery route in peptide research and approved peptide therapeutics. Subcutaneous injection typically achieves 65% to 100% bioavailability for most therapeutic peptides, making it the reference standard in clinical development. Insulin, semaglutide, and octreotide are all administered subcutaneously in their approved formulations.

The subcutaneous route bypasses first-pass hepatic metabolism and gastrointestinal degradation, which are the two largest barriers to oral peptide delivery. Absorption from subcutaneous tissue depots is generally predictable, though it varies with injection site, local blood flow, and peptide formulation. Published pharmacokinetic studies for peptides such as CJC-1295 and ipamorelin have primarily used subcutaneous administration, as discussed in the Peptide Register's coverage of growth hormone secretagogue research.

One limitation: subcutaneous delivery requires sterile preparation and injection technique, which introduces compliance and safety considerations outside of clinical settings.

Oral Delivery: High Convenience, Low Bioavailability

Oral bioavailability for unmodified peptides is generally below 1% to 2% due to gastric acid degradation and enzymatic hydrolysis. The gastrointestinal tract contains pepsin, trypsin, chymotrypsin, and numerous brush-border peptidases that rapidly degrade peptide sequences before absorption can occur.

Oral semaglutide (Rybelsus) represents a notable exception, using a permeation enhancer (SNAC, or sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to achieve clinically meaningful absorption. Even with this formulation technology, oral semaglutide achieves only approximately 0.4% to 1% absolute bioavailability according to published pharmacokinetic analyses. Oral semaglutide achieves approximately 0.4% to 1% bioavailability despite using advanced permeation enhancer technology. This low figure requires high oral doses relative to the subcutaneous formulation.

Strategies under investigation to improve oral peptide bioavailability include enteric coatings, protease inhibitor co-formulations, nanoparticle encapsulation, and cell-penetrating peptide conjugation. Most of these remain in preclinical or early clinical stages, and long-term safety data for many permeation enhancer systems are limited.

Intranasal Delivery: A Middle Ground With Caveats

Intranasal delivery offers a non-invasive alternative with bioavailability that typically falls between oral and subcutaneous routes. Published data suggest intranasal peptide bioavailability ranges from approximately 1% to 25%, depending on molecular weight, formulation, and mucosal absorption enhancers. Intranasal peptide bioavailability ranges from approximately 1% to 25% depending on molecular weight and formulation factors.

Desmopressin and oxytocin are two peptides with approved intranasal formulations. Intranasal desmopressin shows approximately 3% to 5% bioavailability relative to intravenous administration, according to published pharmacokinetic studies. The nasal mucosa provides a relatively thin epithelial barrier with rich vasculature, but mucociliary clearance limits contact time with the absorptive surface.

Absorption enhancers such as cyclodextrins and chitosan derivatives have been studied to improve nasal peptide uptake, with some formulations reporting two- to five-fold increases in bioavailability in clinical trials. However, repeated use of absorption enhancers raises questions about long-term nasal mucosal integrity that remain incompletely addressed in the literature.

Evidence Limitations and Regulatory Context

Bioavailability comparisons across routes are complicated by several factors. Many published pharmacokinetic studies use small sample sizes, often fewer than 20 subjects. Formulation differences between studies make direct comparisons difficult. Most novel delivery technologies have been evaluated only in animal models; animal bioavailability data frequently do not predict human absorption accurately.

From a regulatory standpoint, the route of administration is a defining characteristic of a drug product's approval. Changing the delivery route for an approved peptide typically requires new clinical trials demonstrating safety and efficacy. Researchers evaluating peptide literature should note the administration route used in each study, as findings from subcutaneous studies cannot be assumed to apply to oral or nasal formulations of the same compound. For more on interpreting study methodology, the Peptide Register offers guidance on reading peptide research critically.

Bioavailability is one of several pharmacokinetic parameters catalogued across peptide profiles on the Peptide Register. Understanding how delivery method shapes absorption is essential context for any evidence-based evaluation of peptide research, though it is only one piece of a larger pharmacokinetic and regulatory picture.